Skip to main content

Advertisement

Table 1 Baseline characteristics of patients before starting medication with a SGLT2 inhibitor

From: Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy

Variable Value
Number of patients 27 Empagliflozin 18 (1 × 5 mg; 5 × 10 mg; 12 × 25 mg) Dapagliflozin 9 (1 × 5 mg; 8 × 10 mg)
Age (years) 58 (52; 68)
Sex (male) 12 (43%)
BMI (kg/m2) 36.3 (32.6; 46.1)
Body weight (kg) 101.9 (87.8; 128.6)
Blood pressure
 Systolic (mmHg) 141 (129; 153)
 Diastolic (mmHg) 88 (76; 99)
Heart rate (1/min) 78 (70; 88)
Antidiabetic medication
 Insulin 20 (71.5%)
 Metformin 26 (92.9%)
 DPP4 inhibitor 12 (42.9%)
 GLP1 agonist 7 (25%)
Therapy with RAAS inhibitor 25 (93%)
 ACE inhibitor 20 (74%)
 Angiotensin II receptor antagonist 5 (18%)
Statin therapy 15 (56%)
HbA1c (%) 9.1 (8.1; 10.9)
Creatinine (mg/dL) 0.7 (0.6; 0.9)
Proteinuria (mg/g creatinine) 124 (78; 185)
Hematocrit (%) 42 (39; 44)
Uric acid (mg/dL) 4.7 (4.3; 5.9)
Cholesterol (mg/dL) 172 (160; 200)
 HDL cholesterol (mg/dL) 46 (37; 54)
 LDL cholesterol (mg/dL) 104 (92; 135)
Macrovascular complications: history of
 Coronary artery disease/myocardial infarction 10 (37%)
 Stroke 2 (7%)
 Peripheral artery disease 1 (4%)
Microvascular complications: history of
 Diabetic retinopathy 1 (4%)
 Diabetic nephropathy 8 (31%)
 Diabetic neuropathy 6 (23%)
  1. Values reported are n (%) for categorical variables and median (interquartile range) for continuous variables
  2. RAAS renin–angiotensin–aldosterone system, ACE angiotensin converting enzyme, HDL high density lipoprotein, LDL low density lipoprotein